Joshua Denson, MD
Pulmonary Disease · New Orleans, LANPI 1619268497
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and gifts — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 65.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $1,003 and has fallen 95.7% since, to $43 in 2025. That places this record below the midpoint for pulmonary disease clinicians in LA, where the typical reported total is $3,696.
Across 11 payments — averaging $152.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$315
- Mallinckrodt Enterprises LLC$116
- Stryker$43
- Livanova USA, Inc.$40
- Genentech USA, Inc.$36
- plus $30 from 1 others
Across 14 payments — averaging $15,722 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kiniksa Pharmaceuticals, Ltd.$198K
- Dompe Farmaceutici S.p.a.$22K
What the payments were for
- Consulting fees$97358%
- Food & beverage$67440%
- Gifts$302%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,096 |
| GSK | 3 | $315 |
| Mallinckrodt Enterprises LLC | 1 | $116 |
| Stryker | 1 | $43 |
| Livanova USA, Inc. | 1 | $40 |
| Genentech USA, Inc. | 2 | $36 |
| Merz North America, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,677 in reported general payments places this provider in the 35th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in New Orleans
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Susan GunnNew Orleans$28K
- David PattenNew Orleans$12K
- Yasin KhanNew Orleans$12K
- Ross KlingsbergNew Orleans$11K
- Nereida ParadaNew Orleans$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.